ChinaTalk Chinese Peptides (Reported Podcast Special Edition!)
39 snips
Feb 13, 2026 
Aaron Kesselheim, Harvard physician and FDA policy expert, and Hamilton Morris, science journalist and chemist, dive into the world of Chinese peptides. They explore undercover sourcing, gray-market chemistry, regulatory gaps, industrial manufacturing in China, biohacking trends like BPC-157, and the tangled debate over enforcement versus access.
AI Snips
Chapters
Transcript
Episode notes
Peptides Are A Huge, Diverse Category
- “Peptide” covers a vast universe of molecules with wildly different effects and uses.
- Insulin and semaglutide are peptides, showing the category includes both common medicines and experimental compounds.
Undercover On Xiaohongshu Revealed Fast Responses
- Irene Zhang went undercover on Xiaohongshu and followed ten peptide factory accounts; all followed back within a day.
- Vendors quickly pushed WhatsApp, showed production videos, and claimed 10-day U.S. shipping with a 10-vial minimum.
Gray Market Undercuts Legit Drug Prices
- Chinese suppliers sell FDA-approved GLP-1 analogs like tirzepatide at tiny fractions of U.S. retail price.
- They also offer larger vials and unregulated dosages that raise safety concerns.